The recent insider sale of RxSight shares and the absence of insider purchases over the last year raise concerns about the company's outlook. Despite significant insider ownership, the lack of insider buying does not inspire confidence in the company's prospects.
$テスラ(TSLA.US)$— Shares fell 1.2% after U.S. safety regulators said Tesla will recall more than 2 million vehicles to fix issues with its driver assistance system. The electric vehicle maker will send out a software update to fix the problem, which impacts models Y, S, 3 and X produced between Oct. 5, 2012 and Dec. 7, 2023. $ファイザー(PFE.US)$— The biopharmaceutical stock dropped 7.4% after Pfizer issued full-year guidance for adjusted earnings ...
Investor confidence in RxSight appears bolstered by its high future revenue growth expectations and strong performance, resulting in a high P/S ratio. Investors seem willing to pay more for anticipated growth.
The company seems well equipped to manage its cash burn, potentially securing more funds for its expansion with minimal dilution or borrowing. Revenue growth paints a bright future for the firm, while the slight reduction in cash burn isn't concerning, given its mid-term expenditure needs.
Despite recent insider selling, the insiders still own shares worth about US$105m, or 11% of the company. However, the absence of insider buying raises cautiousness about the stock's outlook.
Gainers: •$カヌー(GOEV.US)$+71.3% (receives purchase order of 4500 Canoo Electric Delivery Vehicles from Walmart) •$アルデイラ セラピューティクス(ALDX.US)$+14.1% (achieved primary endpoints in dry eye disease chamber crossover clinical trial) •$ウェストポート フュエル システムズ(WPRT.US)$+10.9% (awarded 38 mln program) •$グリーンウイッチ ライフサイエンシズ(GLSI.US)$+5.9% (FDA has removed the clinical hold permitting the Flamingo-01 Phase III clinical trial to proceed...
レックスサイトに関するコメント
In reaction to earnings/guidance:
• $GOODRXホールディングス(GDRX.US)$ +38.5%, $エドジオ(EGIO.US)$ +13.5%, $レモネード(LMND.US)$ +10.7%, $デスクトップ メタル A(DM.US)$ +8.5%, $ショックウェーブ メディカル(SWAV.US)$ +8.2%, $パブマティック A(PUBM.US)$ +8.1%, $オラプレックス(OLPX.US)$ +7%, $ビビッド シーツ(SEAT.US)$ +6.4%, $ノーブル(NE.US)$ +6.3%, $アスペン テクノロジー(AZPN.US)$ +5.4%, $AAON(AAON.US)$ +5%, $ハドベイ ミネラルズ(HBM.US)$ +5%, $Vivint Smart Home(VVNT.US)$ +4.9%, $Vivint Smart Home(VVNT.US)$ +4...
• $カヌー(GOEV.US)$ +71.3% (receives purchase order of 4500 Canoo Electric Delivery Vehicles from Walmart)
• $アルデイラ セラピューティクス(ALDX.US)$ +14.1% (achieved primary endpoints in dry eye disease chamber crossover clinical trial)
• $ウェストポート フュエル システムズ(WPRT.US)$ +10.9% (awarded 38 mln program)
• $グリーンウイッチ ライフサイエンシズ(GLSI.US)$ +5.9% (FDA has removed the clinical hold permitting the Flamingo-01 Phase III clinical trial to proceed...
まだコメントはありません